As the Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b2) vaccines become available to patients with autoimmune diseases and SLE, practitioners will have to inform them about the safety and efficacy of these vaccines. Here we discuss the challenges of applying vaccine data to patients with autoimmune diseases and the evidence available in the literature that may help in the decision process.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941677 | PMC |
| http://dx.doi.org/10.1136/lupus-2021-000479 | DOI Listing |
Publication Analysis
Top Keywords
vaccines patients
8
patients autoimmune
8
autoimmune diseases
8
sars-cov-2 vaccines
4
patients sle
4
sle moderna
4
moderna mrna-1273
4
mrna-1273 pfizer/biontech
4
pfizer/biontech bnt162b2
4
bnt162b2 vaccines
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!